Source: StreetInsider

Press Release: Loxo Oncology : New England Journal of Medicine Publishes BRUIN Phase 1/2 Trial Data for Pirtobrutinib in BTK Inhibitor Pre-Treated Adult Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

INDIANAPOLIS, July 6, 2023 /PRNewswire/ --Â Loxo@Lilly, the...

Read full article »
Loxo Oncology's Competitors | Loxo Oncology's News | Loxo Oncology's Financials
Stay up-to-date with the latest news on Loxo Oncology
Est. Annual Revenue
$100-500M
Est. Employees
500-1.0K
Jacob S. Van Naarden's photo - CEO of Loxo Oncology

CEO

Jacob S. Van Naarden

CEO Approval Rating

82/100

Read more
Stay up-to-date with the latest news on Loxo Oncology